Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer
Studies Shed Light On Racial Disparities Between Blacks, Whites With Breast Cancer
Shorter, Simpler Consent Form Proposed For Phase I Trials
How Much Is Life Worth? The $440 Billion Question
Sunitinib Prolongs Survival In Poor Prognosis, Study Finds
Breast MRI Recipients More Likely To Choose Mastectomy
Opioid Pain Reliever Approved With Risk Reduction Plan
NCI Cooperative Group Clinical Trials Approved
Trending Stories
- Preparing to take care of each other in ways we never imagined
- 20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect
- Federal judge blocks Trump administration’s move to limit indirect costs to 15% for NIH-funded institutions
The move could gut academic cancer research - From the chairs of ECOG-ACRIN: A perspective on indirect costs
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty